Article
Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.
Breast cancer research and treatment - 1 Nov 2015
Blackwell Kimberly, Burris Howard, Gomez Patricia, Lynn Henry N, Isakoff Steven, Campana Frank, Gao Lei, Jiang Jason, Macé Sandrine, Tolaney Sara M
Abstract excerpt
This phase I/II dose-escalation study evaluated the efficacy, safety, and pharmacokinetics of pilaralisib (SAR245408), a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor, or voxtalisib (SAR245409), a PI3K and mammalian target of rapamycin inhibitor, in combination with letrozole in hormone-receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative, non-steroidal aromatase...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.